Bone Health
End-to-End Support of Studies involving DXA: Obesity, Osteoporosis, Oncology, Infection disease, Nutrition and Metabolism Studies
1. Hero Section
1. Hero Section: Bone Health Imaging Support for Clinical Trials
Sub-title: Example – Turning bone health data into reliable, trial-ready evidence for therapeutic success
Primary CTA: Talk to an Expert: contact@ia-grp.com
Imaging for Safety, Efficacy, and Accelerated Approvals
2. Problem & Solution Overview (Context Setting)
Image Analysis Group (IAG) specializes in building imaging-powered differentiation strategies for novel drug candidates and biosimilars, with a strong focus on safety and efficacy trials in bone health, obesity, osteoporosis, sarcopenia, and related areas.
IAG’s team experience with using DXA, MRI, Fibroscan and X-ray in clinical trials spans over 20 years, with the company supporting large registrational studies and early phase projects. Leading proficiency with DXA imaging allows for precise measurement of lean mass, fat mass, and bone density changes, which are crucial metrics in evaluating the efficacy of obesity drugs.
Discover how you can drive significant cost savings (up to 35% trial budget reduction) and improve your chances of success through advanced patient stratification strategies that reduce trial length and cost.
Purpose: Showcase track record and credibility for trust-building.
Content ideas:
- Fact/metric bar (e.g., trials supported, years of experience, global coverage)
- Compliance and certifications
- CTA (invite discussion or contact)
Case Study:
5. Case Studies (Social Proof)
One specific study, involving DXA analysis makes a vivid example. In 2021, IAG was contacted by a biotech company to support their Phase III trial. The objective was to utilize X-ray and DXA scans for combined eligibility as one of the criteria for the inclusion / exclusion of patients in their protocol. The Sponsor was looking for experts in the field, who can bring global network of sites, and execute screening with speed. IAG’s team partnered with the CRO and together we embarked on accelerating recruitment, opening out network of 750 obesity focused sites. The Study recruited faster than expected, saving Sponsor significant time and money. The data is currently being finalized to be submitted for regulatory review.
Given market dynamics, our latest focus has been on the safety and efficacy trials targeting bone health, obesity, OP, advanced oncology, sarcopenia, IO, spinal fusion.
Value of Partnering with IAG
7. Educational Resources (Engagement)/
8. FAQs (Objections Handling)
Unparalleled Imaging Expertise
With over 20 years of experience in DXA, MRI, Fibroscan, and X-ray for clinical trials, IAG excels in both large registrational studies and early-phase projects.
Award-Winning Data Management Platform
IAG’s DYNAMIKA platform efficiently processes imaging data, supports all trial stakeholders, and delivers results via reports or dashboards, enabling rapid decision-making.
Time-Sensitive Solutions
Understanding the critical nature of time in clinical development, IAG provides transparent, efficient support to partners, readers, and sponsors throughout the trial process.
Global Support, Local Focus
We placed our team of imaging specialists in geographically important hubs (USA, EU, Asia, UK), which enables them to provide efficient answers to the sites and support global trials, with speed.
Value-Driven Partnerships
We prioritize delivering the highest quality data at competitive cost. We thrive to build long term relationships with our partners and clients.
Book a 30‑minute DXA endpoint strategy session
9. Bottom Call to Action (Conversion)
Planning a clinical trial involving DXA or other imaging modalities to assess safety and efficacy? Discover how IAG’s 20+ years of experience, global site network, and award-winning DYNAMIKA platform can streamline your imaging workflow and accelerate your trial outcomes.